JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Prognostic significance of PD-L1 and CD45RO+ cells in glioblastoma: The modulating role of MMR status

  • 0Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Journal of Neuroimmunology +

|

June 24, 2025

|

June 24, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

High PD-L1 expression and CD45RO+ cell infiltration are key prognostic indicators for glioblastoma (GBM) patients, especially those proficient in mismatch repair. These findings may guide personalized immunotherapies for improved GBM outcomes.

Area Of Science

  • Neuro-oncology
  • Immunology
  • Biomarker Discovery

Background

  • Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis and limited therapeutic options.
  • Immune checkpoint molecules and tumor-infiltrating lymphocytes are crucial prognostic biomarkers in GBM.
  • Identifying reliable prognostic markers is essential for improving patient outcomes.

Purpose Of The Study

  • To investigate the prognostic roles of PD-L1, CD45RO+ cells, and other biomarkers in Glioblastoma.
  • To evaluate the association between these biomarkers and overall survival (OS) in GBM patients.
  • To explore the influence of mismatch repair (MMR) proficiency and IDH mutation status on biomarker prognostic value.

Main Methods

  • Immunohistochemical (IHC) staining was performed on 63 formalin-fixed paraffin-embedded (FFPE) GBM tissue samples.
  • Expression levels of PD-1, PD-L1, CD45RO, mismatch repair (MMR) proteins, and Ki-67 were analyzed.
  • Cox regression analysis was used to assess the prognostic impact of the evaluated biomarkers.

Main Results

  • Limited immune infiltration was observed in the GBM tumor tissues.
  • High PD-L1 expression (HR: 1.926) and elevated CD45RO+ cell infiltration (HR: 2.122) were significantly associated with reduced overall survival (OS).
  • PD-L1 and CD45RO+ cells demonstrated a stronger prognostic impact in MMR-proficient patients; IDH mutation status was the sole independent prognostic marker in MMR-deficient cases.

Conclusions

  • PD-L1 and CD45RO+ cells are significant prognostic biomarkers for GBM, particularly in MMR-proficient patients.
  • These findings highlight the potential for personalized immunotherapies targeting immune checkpoints to enhance GBM treatment efficacy.
  • Further investigations are needed to elucidate the therapeutic implications of these biomarkers across different GBM subgroups.

Keywords: